Immunitas Therapeutics

company

About

Immunitas Therapeutics is a single cell genomics-based drug discovery company that modulates oncology targets.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$39M
Industries
Biotechnology,Health Care,Life Science,Therapeutics
Founded date
Jan 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with
challenging, complex cancers.
Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problem and unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.

At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$97M
Immunitas Therapeutics has raised a total of $97M in funding over 2 rounds. Their latest funding was raised on Aug 18, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 18, 2021 Series B $58M 1 Detail
Nov 22, 2019 Series A $39M 2 Bayer Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Immunitas Therapeutics is funded by 2 investors. Bayer and Evotec are the most recent investors.
Investor Name Lead Investor Funding Round
Bayer Yes Series A
Evotec Series B